MARKET WIRE NEWS

Ultralife Corporation Reports Third Quarter Results

MWN-AI** Summary

Ultralife Corporation (NASDAQ: ULBI) reported its financial results for the third quarter ending September 30, 2025, highlighting a significant increase in sales and the impact of operational challenges. The company's sales reached $43.4 million, a notable 21.5% increase from $35.7 million during the same period in 2024. When excluding the contribution from Electrochem Solutions, organic growth was more modest at 2.5%.

The company's gross profit stood at $9.6 million or 22.2% of revenue, a decrease from 24.3% a year prior, primarily due to manufacturing inefficiencies linked to supply chain issues. Additionally, Ultralife incurred an operating loss of $1.0 million, largely due to one-time costs associated with the closure of their Calgary facility, whereas they reported operating income of $0.5 million in Q3 2024. This contributed to a GAAP loss per share of $0.07, compared to a profit of $0.02 per share last year.

Adjusted EBITDA was recorded at $2.0 million, slightly up from $1.9 million year-over-year. The backlog at the end of Q3 2025 was $90.1 million, reflecting growth from $84.5 million in the previous quarter. Notably, Ultralife has initiated the closure of its Calgary facility, projected to yield annual savings of approximately $0.8 million by reducing labor and leasing costs.

CEO Mike Manna emphasized the need for intensified process improvements to address profitability impacts caused by supply chain disruptions and to capitalize on new product opportunities amid a growing pipeline of multi-year programs. Overall, while revenue growth is strong, operational challenges remain a concern for the company moving forward.

MWN-AI** Analysis

Ultralife Corporation (NASDAQ: ULBI) reported mixed third-quarter results for 2025, highlighting both growth and ongoing operational challenges. The company achieved a revenue increase of 21.5% year-over-year to $43.4 million, significantly boosted by its recent acquisition of Electrochem Solutions. However, organic growth was modest at 2.5%, indicating potential concerns in its core markets.

The gross profit margin decreased to 22.2%, down from 24.3% in the previous year, primarily due to manufacturing inefficiencies and quality issues affecting the Battery & Energy Products segment. While the company is focused on operational improvements, the recent operating loss of $1 million reflects the one-time costs associated with closing the Calgary facility, which may deter short-term investor confidence.

Investors should closely monitor the company's ability to convert its strong backlog of $90.1 million into revenue and manage the ongoing operational challenges. The anticipated cost savings of approximately $0.8 million annually following the Calgary closure could provide some relief, but the effectiveness of the lean initiatives mentioned by management will be critical.

Ultralife's emphasis on advancing new products, especially in the government/defense sectors, offers a long-term growth narrative, but success hinges on resolving supply chain disruptions and improving manufacturing efficiency. The recent dip in earnings per share to a loss of $0.07 suggests market volatility, which could create cautious sentiment among investors.

Overall, while Ultralife Corporation's growth trajectory is favorable, potential investors should adopt a cautious stance, keeping an eye on operational improvements and market conditions. The stock might be worth considering for those with a long-term view, particularly if the company can stabilize its operations and increase its organic revenue growth in the upcoming quarters.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: GlobeNewswire

NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results:

  • Sales of $43.4 million increased 21.5% from $35.7 million for the third quarter of 2024; excluding Electrochem, sales of $36.6 million increased 2.5%
  • Gross profit of $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the third quarter of 2024
  • Operating loss of $1.0 million, reflecting one-time non-recurring costs of $1.1 million, including a $.5 million provision to close our Calgary facility, compared to operating income of $0.5 million for the third quarter of 2024
  • GAAP EPS of ($0.07) compared to $0.02 for the third quarter of 2024
  • Adjusted EBITDA of $2.0 million compared to $1.9 million for the third quarter of 2024
  • Backlog of $90.1 million exiting the third quarter of 2025 compared to $84.5 million exiting the second quarter of 2025

During the third quarter of 2025, Ultralife made the decision to close its battery pack assembly facility located in Calgary, Canada. Accordingly the Company recorded a $.5 million charge to cover employee severance and termination costs, the remaining lease costs which run through July 31, 2026 and the estimated costs to close the facility and relocate the equipment and inventory to the Company’s facility in Houston, Texas. Management expects to complete the closure in the first quarter of 2026 and to realize estimated annual savings of approximately $.8 million thereafter primarily resulting from the reduction of labor and the elimination of the leased facility.

“Although revenue grew 2.5% organically and 21.5% including the Electrochem acquisition for the third quarter, supply chain issues caused manufacturing inefficiencies in our Battery & Energy Products business and orders continued to be delayed in our Communications Systems business, both of which impacted overall profitability. In response, we are intensifying our lean and process improvement initiatives, improving supply chain resiliency and rationalizing our manufacturing operations,” said Mike Manna, President and Chief Executive Officer.

“These actions are critical to ensuring we are best prepared to optimize the operating leverage of our business model as we advance several new products into qualification and production, and capitalize on an expanding pipeline of opportunities consisting primarily of large, multi-year programs,” added Manna. “Our priorities remain converting long-term new product development efforts into revenue, advancing vertical integration in the oil & gas segment, and maintaining a strong focus on operational efficiency initiatives to deliver sustainable profitable growth and maximizing the value of our global brand.”

Third Quarter 2025 Financial Results

Revenue was $43.4 million, an increase of $7.7 million, or 21.5%, as compared to revenue of $35.7 million for the third quarter of 2024. Battery & Energy Products sales increased 22.8% to $39.9 million compared to $32.5 million last year reflecting the inclusion of Electrochem Solutions, Inc. (“Electrochem”). Excluding Electrochem, Battery & Energy Products sales increased 1.9% with government/defense sales increasing 19.0%, reflecting strong demand from a U.S.-based global prime, partially offset by a 5.7% decrease in commercial sales, primarily reflecting declines in oil & gas and medical sales. Communications Systems sales increased 8.2% to $3.4 million compared to $3.2 million for the same period last year.

Gross profit was $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 22.1%, compared to 24.7% last year, primarily due to manufacturing inefficiencies resulting from quality issues associated with some incoming raw materials lowering factory throughput at some of our locations and less favorable sales mix. Communications Systems gross margin was 23.3% compared to 20.0% last year, primarily due to product mix.

Operating expenses were $10.6 million, compared to $8.2 million for the third quarter of 2024, reflecting the inclusion of Electrochem and one-time non-recurring costs of $1.1 million related to the closing of our Calgary facility, costs related to our acquisition of Electrochem and transition to Ultralife systems, and litigation expenses incurred for our cyber insurance claim. Operating expenses were 24.4% of revenue compared to 22.9% of revenue for the year-earlier period. Excluding the one-time costs, operating expenses were 21.9% of revenues for the third quarter of 2025.

Operating loss was $1.0 million compared to operating income of $.5 million last year, primarily resulting from the one-time non-recurring expenses incurred and lower gross margin for our Battery & Energy Products segment in 2025.

Other expense, reported below operating income was $.8 million, comprised of interest expense from the financing of our Electrochem acquisition on October 31, 2024 and foreign currency gains from the strengthening of the U.S. dollar, compared to $.2 million for the same period last year.

Net (loss) income attributable to Ultralife Corporation was ($1.2) million or ($0.07) per basic and diluted share on a GAAP basis, compared to $.3 million or $0.02 per diluted share for the third quarter of 2024.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $2.0 million for the third quarter of 2025, or 4.7% of sales, compared to $1.9 million, or 5.4% of sales, for the year-earlier period. On a trailing twelve-month basis, adjusted EBITDA was $15.5 million or 8.3% of sales.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com .

Conference Call Information

Ultralife will hold its third quarter earnings conference call today at 8:30 ET.

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register-conf.media-server.com/register/BI0301fd92021249ef830e0c9c7be9f917 . This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com . For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions including the impact of tariffs and inflation, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions, delays or material price increases in our supply of raw materials and components due to business conditions, new or additional tariffs, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.


ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands)
(Unaudited)
ASSETS
September 30,
2025
December 31,
2024
Current Assets:
Cash $9,260 $6,854
Trade Accounts Receivable, Net 30,929 29,370
Inventories, Net 52,747 51,363
Prepaid Expenses and Other Current Assets 7,683 9,573
Total Current Assets 100,619 97,160
Property, Plant and Equipment, Net 40,536 40,485
Goodwill 45,336 45,006
Other Intangible Assets, Net 23,407 24,557
Deferred Income Taxes, Net 8,212 8,413
Other Non-Current Assets 4,136 4,830

Total Assets
$222,246 $220,451

LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts Payable $14,164 $14,160
Current Portion of Long-Term Debt 3,781 2,750
Accrued Compensation and Related Benefits 2,935 2,911
Accrued Expenses and Other Current Liabilities 12,818 9,470
Total Current Liabilities 33,698 29,291
Long-Term Debt, Net 46,518 51,502
Deferred Income Taxes 1,358 1,443
Other Non-Current Liabilities 3,239 4,028
Total Liabilities 84,813 86,264
Shareholders' Equity:
Common Stock 2,109 2,107
Capital in Excess of Par Value 192,622 191,828
Accumulated Deficit (32,918) (34,442)
Accumulated Other Comprehensive Loss (3,058) (4,006)
Treasury Stock (21,492) (21,492)
Total Ultralife Equity 137,263 133,995
Non-Controlling Interest 170 192
Total Shareholders’ Equity 137,433 134,187
Total Liabilities and Shareholders' Equity $222,246 $220,451


ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In Thousands Except Per Share Amounts)
(Unaudited)
Three-Month Period Ended Nine-Month Period Ended
September 30, September 30, September 30, September 30,
2025 2024 2025 2024
Revenues:
Battery & Energy Products $39,946 $32,529
$132,134 $104,201
Communications Systems 3,425 3,165 10,544 16,403
Total Revenues 43,371 35,694 142,678 120,604
Cost of Products Sold:
Battery & Energy Products 31,126 24,482 101,039 77,215
Communications Systems 2,626 2,530 7,674 11,674
Total Cost of Products Sold 33,752 27,012 108,713 88,889
Gross Profit 9,619 8,682 33,965 31,715
Operating Expenses:
Research and Development 2,855 2,101 7,577 5,854
Selling, General and Administrative 7,715 6,070 21,684 17,370
Total Operating Expenses 10,570 8,171 29,261 23,224
Operating (Loss) Income (951) 511 4,704 8,491
Other Expense 800 158 2,896 685
(Loss) Income Before Income Taxes (1,751) 353 1,808 7,806
Income Tax (Benefit) Provision (504) 74 306 1,630
Net (Loss) Income (1,247) 279 1,502 6,176
Net (Loss) Income Attributable to Non-Controlling Interest (27) 21 (22) 58
Net (Loss) Income Attributable to Ultralife Corporation ($1,220) $258 $1,524 $6,118
Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Basic ($.07) $.02 $.09 $.37
Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Diluted ($.07) $.02 $.09 $.37
Weighted Average Shares Outstanding – Basic 16,646 16,625 16,638 16,530
Weighted Average Shares Outstanding – Diluted 16,646 16,874 16,699 16,742


Non-GAAP Financial Measures

Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.



ULTRALIFE CORPORATION AND SUBSIDIARIES
CALCULATION OF ADJUSTED EBITDA
(Dollars in Thousands)
(Unaudited)
Three-Month Period Ended Nine-Month Period Ended
September 30,
2025
September 30,
2024
September 30,
2025
September 30,
2024
Net (Loss) Income Attributable to Ultralife Corporation ($1,220) $258 $1,524 $6,118
Adjustments:
Interest Expense, Net 992 173 3,016 1,111
Income Tax (Benefit) Provision (504) 74 306 1,630
Depreciation Expense 1,008 765 2,966 2,294
Amortization Expense 411 229 1,226 684
Stock-Based Compensation Expense 236 170 698 490
Severance and Other Costs for Plant Closure 491 - 641 -
Acquisition and Other Non-Recurring Costs 594 250 1,112 -
Non-Cash Purchase Accounting Adjustment 40 - 120 250
Adjusted EBITDA $2,048 $1,919 $11,609 $12,577


Company Contact:
Ultralife Corporation
Philip A. Fain
(315) 210-6110
pfain@ulbi.com
Investor Relations Contact:
Alliance Advisors IR
Jody Burfening/Alex Villalta
(212) 838-3777
avillalta@allianceadvisors.com

FAQ**

Given the reported increase in revenue for Ultralife Corporation ULBI, what specific strategies are being implemented to address the manufacturing inefficiencies in the Battery & Energy Products segment that impacted profitability?

Ultralife Corporation is implementing automation enhancements, optimizing supply chain management, and increasing workforce training to address manufacturing inefficiencies in the Battery & Energy Products segment and improve profitability amidst reported revenue growth.

How does Ultralife Corporation ULBI plan to capitalize on the expanding pipeline of opportunities from large, multi-year programs following the one-time costs associated with the Calgary facility closure?

Ultralife Corporation (ULBI) aims to leverage its operational efficiencies and reduced overhead from the Calgary facility closure to focus on strategic investments and collaborations that target high-value, long-term contracts in defense and commercial sectors.

With Ultralife Corporation ULBI experiencing a decline in commercial sales, particularly in the oil & gas and medical sectors, what measures are being taken to diversify and strengthen these revenue streams?

Ultralife Corporation is focusing on diversifying its revenue streams by expanding into new markets, enhancing product offerings, investing in R&D for innovative solutions, and seeking partnerships to mitigate the decline in commercial sales in the oil & gas and medical sectors.

Considering the goals of improving supply chain resiliency and advancing new product development, what are the key performance indicators Ultralife Corporation ULBI will use to measure success in these areas over the upcoming quarters?

Ultralife Corporation (ULBI) will likely focus on key performance indicators such as supply chain lead times, inventory turnover, new product time-to-market, customer satisfaction scores, and revenue growth from new products to measure success in improving resiliency and development.

**MWN-AI FAQ is based on asking OpenAI questions about Ultralife Corporation (NASDAQ: ULBI).

Ultralife Corporation

NASDAQ: ULBI

ULBI Trading

4.16% G/L:

$6.26 Last:

29,287 Volume:

$6.04 Open:

mwn-alerts Ad 300

ULBI Latest News

ULBI Stock Data

$108,051,666
9,989,368
7.68%
13
N/A
Industrial Goods
Industrials
US
Newark

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App